Drug Prices, Patent Cliffs, and Generic Competition: The Definitive US Pharma Strategy Guide
The US pharmaceutical market runs on a single, brutal equation: time equals money, and money equals survival. A company that […]
Valuation of Pharmaceutical Companies: A Comprehensive Analysis of Key Considerations
Welcome to the most volatile, high-stakes, and strategically critical discipline in modern business: the valuation of pharmaceutical and biotechnology companies.
Valuation of Pharmaceutical Companies: A Comprehensive Analysis of Key Considerations Read Post »
Generic Drug Opportunities: The Complete Framework for IP-Driven Market Entry, Regulatory Arbitrage, and Portfolio Construction
1. Executive Summary and Scope Finding a winning generic drug opportunity requires more than scanning the Orange Book for upcoming
Generic Drug Licensing and Repurposing: The Complete IP, Regulatory, and Commercial Playbook
Patent cliffs destroy revenue overnight. Generic competition can erase 80% of a blockbuster’s sales within twelve months of loss of
First Generic Launch has Significant First-Mover Advantage Over Later Generic Drug Entrants
Generic drugs perform better financially if they get to market first. The advantage is amplified if they get there more than one month ahead of competitors.
6 Ways to Maximize Product Value as Loss of Exclusivity Approaches
Loss of exclusivity doesn’t mean the end of the income stream for branded drugs. Here’s how drug companies can mitigate the effects of drug patent expiration.
6 Ways to Maximize Product Value as Loss of Exclusivity Approaches Read Post »
The 505(b)(2) Goldmine: How Pharma Extracts Maximum IP Value from Modified Drugs
I. The 505(b)(2) Pathway: What It Is and Why Analysts Keep Undervaluing It The 505(b)(2) pathway is the most structurally
The 505(b)(2) Goldmine: How Pharma Extracts Maximum IP Value from Modified Drugs Read Post »
Generic Drug Market Entry in Europe: The Definitive Guide to Tailored Strategy, IP Navigation, and Country-Level Market Access
Generic drug makers must tailor European market entry strategies to each country. Moreover, they must address the sequence in which they want to enter markets.
Drug Patent Cliffs, Generic Wars, and 180-Day Gold: The Complete Pharma Market Entry Playbook
1. Branded vs. Generic Drugs: Two Businesses, One Market The global pharmaceutical market crossed $1.6 trillion in 2024 and is
